- Previous Close
3.0300 - Open
3.0450 - Bid 3.1000 x --
- Ask 3.2050 x --
- Day's Range
3.0450 - 3.0450 - 52 Week Range
2.6750 - 4.9550 - Volume
317 - Avg. Volume
47 - Market Cap (intraday)
104.717M - Beta (5Y Monthly) 1.58
- PE Ratio (TTM)
-- - EPS (TTM)
-1.0800 - Earnings Date Mar 26, 2025 - Mar 31, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
Achieve Life Sciences, Inc., a clinical-stage pharmaceutical company, develops and commercializes cytisinicline for smoking cessation and nicotine addiction. The company offers cytisinicline, a plant-based alkaloid that interacts with nicotine receptors in the brain that reduce the severity of nicotine withdrawal symptoms. It has license and supply agreement with Sopharma AD and University of Bristol Achieve Life Sciences, Inc. is based in Vancouver, Canada.
www.achievelifesciences.comRecent News: SP4P.F
View MorePerformance Overview: SP4P.F
Trailing total returns as of 1/31/2025, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: SP4P.F
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: SP4P.F
View MoreValuation Measures
Market Cap
108.17M
Enterprise Value
76.36M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
3.47
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-54.09%
Return on Equity (ttm)
-186.04%
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-32.94M
Diluted EPS (ttm)
-1.0800
Balance Sheet and Cash Flow
Total Cash (mrq)
42.91M
Total Debt/Equity (mrq)
31.37%
Levered Free Cash Flow (ttm)
-14.94M